Publications

Oxazolidinone (OXA-resistant (R) Enterococci Emerging in 2001: Report Patients from the SENTRY Antimicrobial Surveillance Program (USA), Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Potency and Susceptibility for Six Gram-Positive Antimicrobials Tested Against Prevalent Gram-Positive Bacteria Isolated in the Chemotherapy Alliance for Neutropenics and Control of Emerging Resistance (CANCER) Program, Lead author: Mutnick A, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Antimicrobial resistance in viridans group streptococci in Europe, Lead author: Prodhom G, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Antimicrobial Surveillance of Beta-Haemolytic Streptococci in Europe (EU) and North America (NA): Report from the SENTRY Program (2001), Lead author: Biedenbach DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Chemotherapy Alliance for Neutropenics and Controlof Emerging Resistance (CANCER) Program: Initial Report from Haematology-Oncology Hospitals in North America (NA), Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Assessment of Pathogens and Resistance (R) Patterns Among Intensive Care Unit (ICU) Patients in North America (NA): Initial Report from the SENTRY Antimicrobial Surveillance Program (2001), Lead author: Stephen J, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Geographic Variations and Trends in Key Bacteremic Pathogen Resistance (R): Report from the SENTRY Antimicrobial Surveillance Program (1997 – 2001), Lead author: Rhomberg PR, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Occurrence of Blood Stream Infection (BSI) Pathogens and Key Resistances (R) from SENTRY Antimicrobial Surveillance Program, A 5-Year Report, Lead author: Moet G, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Bacterial pathogens isolated from patients with blood stream infection (BSI): 5-year occurrence and antimicrobial susceptibility (S) patterns from the SENTRY Antimicrobial Surveillance Program in Latin America, Lead author: Sader HS, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Carbapenem Resistance (R) in Enteric Bacilli and P. aeruginosa (PSA) in the USA (1999-2002): Report from the MYSTIC Program, Lead author: Mutnick A, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Increasing prevalence of antimicrobial resistant P. aeruginosa isolated in Latin America (LA) medical centers: 5-year report of the SENTRY Antimicrobial Surveillance Program, Lead author: Andrade-Baiocchi S, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Salmonella spp. Blood Stream Infections (BSI) Worldwide: Five-Year Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Stephen J, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Occurrence and Susceptibility (S) Profiles of Pathogens Causing Gastroenteritis (GE) in North America (NA) and Europe (EU): Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Biedenbach DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Frequency of occurrence (FO) and antimicrobial resistance (R) patterns for gastroenteritis pathogens isolated from stool and blood cultures in Latin America: Results of SENTRY Program, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Assessment of the antimicrobial activity of polymyxin B against contemporary Gram-negative bacilli isolated in Latin America: Results of SENTRY Antimicrobial Surveillance Program, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Susceptibility (S) Trends of H. influenzae (HI) and M. catarrhalis (MCAT) Against Orally Administered Antimicrobial Agents: Five Year Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Johnson DM, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Assessment of Quality Assurance (QA) Failure Rates for Commonly Used Diagnostic Media: Results of a Coll. of American Pathologist (CAP) Questionnaire in 2001, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Revision of Linezolid Disk Diffusion Quality Control (QC) Range for Testing S. aureus ATCC 25923: A Seven Center Trial, Lead author: Biedenbach DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Inter-Method Susceptibility Comparisons Produced by Several NationalMethods: Report of Garenoxacin (GRN) Results Produced by Methods from France (F), Germany (G), Spain (SP), Sweden (SW) and UK Versus NCCLS, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Novel phenotypic screening method accurately detects emerging P. aeruginosa (PSA) metallo-(-lactamases (M(L) isolates in Italy: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a New Desfluoroquinolone, Lead author: Rhomberg PR, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Garenoxacin (BMS-284756) Activity Against 8,686 S. pneumoniae (SPN) Including Tentative Susceptibility Testing Criteria, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Emergence of quinolone resistance in S. pneumoniae in Europe: SENTRY Antimicrobial Surveillance Program, 1997-2001, Lead author: Canton R, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

In vitro activity of gemifloxacin (GEMI) against 11,311 clinical bacterial isolates collected from the Latin American region, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Activity of AZD2563, a new oxazolidinone, tested against Gram-positive cocci collected in Latin American medical (LA) centers in 2001, Lead author: Sader HS, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Proposed Susceptibility Testing Criteria for AZD2563, A Novel Long-Acting Oxazolidinone (OXA), Lead author: Anderegg T, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Spectrum and Potency of a New Peptide Deformylase Inhibitor, NVP-PDF386, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Bactericidal Action and Synergy Studies of BAL9141, A Novel Pyrrolidinone-3-ylidenemethyl Cephem, Tested Against Enterococci and Methicillin-Resistant Staphylococci (MRSA), Lead author: Deshpande LM, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Impact of pharmacokinetic (PK) and microbiological variability on the pharmacodynamics of gatifloxacin (GAT) against S. pneumoniae in children, Lead author: Rubino CM, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Initial Descriptions of Linezolid Resistance in Staphylococcus epidermidis and Streptococcus oralis: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Enne V, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Antifungal activity of caspofungin and the new triazoles compared with itraconazole and amphotericin B against 462 recent clinical isolates of Aspergillus and other filamentous fungi, Lead author: Diekema DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Five years of longitudinal global surveillance for Candida spp. infection: Stability of species distribution and fluconazole susceptibility from 1997-2001, Lead author: Diekema DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates, Lead author: Pfaller MA, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Carbapenem and Cefepime Activity Tested Against Ceftazidime- and Ceftriaxone-Resistant Enterobacter spp. Isolates From North America, Latin America, Asia-Pacific, and Europe, 1997-2000: Report From the SENTRY Antimicrobial Surveillance Program, Lead author: Mutnick A, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: Report of the 2001 Data from 15 Medical Centers, Lead author: Rhomberg PR, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Potency and Antimicrobial Spectrum Update for Piperacillin/Tazobactam (2000): Emphasis on its Activity Against Resistant Organism Populations and Generally Untested Species Causing Community-Acquired Respiratory Tract Infections, Lead author: Johnson DM, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Comparative Activity of Garenoxacin (BMS 284756), a Novel Desfluoroquinolone, Tested Against 13,704 Isolates From Community-Acquired Respiratory Tract Infections: Results From the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Widespread Distribution of Plasmid-Mediated CMY-2 AmpC Beta-Lactamase in Human E. coli from the United States, Lead author: Gudlaugsson O, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Genotypic Characterization of Carbapenem-non-Susceptible Acinetobacter spp. Isolated in Latin America, Lead author: Gales AC, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Typing Characterization of Streptococcus pneumoniae (Spn) Non-Susceptible to Cefotaxime (CTX) Isolated in Latin American (LA) Medical Centers, Lead author: Castanheira M, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Intermethod agreement and preliminary quality control guidelines for susceptibility testing AZD2563 by disk diffusion and MIC methods, Lead author: Anderegg T, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Validation of commercial dry-form panels (sensititre) for the susceptibility testing of AZD2563 by disk diffusion and MIC methods, Lead author: Jones RN, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Antimicrobial susceptibilities of H. influenzae and M. catarrhalis causing lower respiratory tract infections: SENTRY Antimicrobial Surveillance Program, Europe 2000, Lead author: Loza E, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 19972000, Lead author: Canton R, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies with gentamicin and vancomycin against staphylococci and streptococci, Lead author: Jones RN, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

In vitro activity of meropenem, imipenem, piperacillin/tazobactam, ciprofloxacin, amikacin, and cefepime against P. aeruginosa and A. baumannii isolated from Brazilian intensive care units- MYSTIC Study Group (Brazil 2001), Lead author: Mendes C, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Emerging resistances among Proteus mirabilis isolates in Europe: Report from the MYSTIC programme (1997-2001), Lead author: Mutnick A, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Antimicrobial Susceptibility Patterns of Beta-Haemolytic and Viridans Group Streptococci: Report From the SENTRY Antimicrobial Surveillance Program (1997-2000), Lead author: Gordon K, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: the SENTRY surveillance program in Europe 2000Europe: Update from SENTRY surveillance program 2000, Lead author: Rodriguez-Villalobos H, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Initial Studies of Resistance Patterns in India: Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program Baseline Results for Multi-Resistant Gram-Negative Bacilli and Endemic Salmonella spp. Isolates, Lead author: Jones RN, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore